The company, an investment arm of the Novo Nordisk Foundation, holds 77% of the voting shares in Novo Nordisk, known for producing the hit obesity drug Wegovy and diabetes drug Ozempic.
Experts believe that quantum computing may prove to be one of the most revolutionary technological achievements of the 21st century.
Tech companies and governments alike have worked to create machines that exploit quantum mechanics and can perform scientific calculations that would otherwise take most computers millions of years to complete.
Announcing the news on Wednesday, Novo Holdings said it wants to lend a hand build an ecosystem of quantum computing startups, with a focus on life sciences companies in the Nordics.
By applying this technology to the development of pharmaceuticals and other life sciences products, quantum computing companies could significantly speed up the drug discovery process.
Soren Moller, seed investment managing partner at Novo Holdings, said: “Quantum technology is a disruptive and transformative field that has the potential to revolutionize various sectors and address global challenges.” He added: “Our ultimate goal is to create, grow and develop sturdy quantum technology companies in the Nordics.”
